V
The startup develops macrocyclic peptides as antiviral agents delivered via a nasopharyngeal spray to treat respiratory viral infections. This targeted therapy enables hospitals to provide effective treatment options for patients suffering from these infections.
Updated 3 months ago
Funding
$360K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops macrocyclic peptides as antiviral agents delivered via a nasopharyngeal spray to treat respiratory viral infections. This targeted therapy enables hospitals to provide effective treatment options for patients suffering from these infections.